{"id":"alendronate-fosamax","safety":{"commonSideEffects":[{"rate":"5–20%","effect":"Gastrointestinal upset (nausea, dyspepsia, abdominal pain)"},{"rate":"1–5%","effect":"Esophageal irritation / ulceration"},{"rate":"1–3%","effect":"Musculoskeletal pain"},{"rate":"1–3%","effect":"Headache"},{"rate":"<1%","effect":"Osteonecrosis of the jaw (rare, long-term use)"}]},"_chembl":{"chemblId":"CHEMBL675","moleculeType":"Small molecule","molecularWeight":"271.08"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bisphosphonate, alendronate is selectively taken up by osteoclasts during bone resorption. Once internalized, it inhibits farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases required for osteoclast function and survival. This leads to decreased bone turnover and increased bone mineral density, making it effective for conditions characterized by excessive bone loss.","oneSentence":"Alendronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and blocking the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:54.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Osteoporosis in men"},{"name":"Glucocorticoid-induced osteoporosis"},{"name":"Paget's disease of bone"}]},"trialDetails":[{"nctId":"NCT07471880","phase":"PHASE2","title":"A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head","status":"ACTIVE_NOT_RECRUITING","sponsor":"ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.","startDate":"2024-12-24","conditions":"Osteonecrosis, Osteonecrosis of the Femoral Head","enrollment":161},{"nctId":"NCT06973109","phase":"PHASE2","title":"Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nitin Agarwal","startDate":"2026-03-20","conditions":"Osteoporosis, Post-menopausal","enrollment":36},{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280},{"nctId":"NCT06016634","phase":"PHASE2","title":"Alendronate for Osteonecrosis in Adults With Sickle Cell Disease","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2026-02-09","conditions":"Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis","enrollment":30},{"nctId":"NCT05764733","phase":"PHASE4","title":"Bone, Exercise, Alendronate, and Caloric Restriction","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-06-08","conditions":"Bone Loss","enrollment":900},{"nctId":"NCT07245381","phase":"PHASE1, PHASE2","title":"Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation","status":"NOT_YET_RECRUITING","sponsor":"Dr. Itay GoorAryeh","startDate":"2025-12","conditions":"Cervix Cancer","enrollment":65},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT05091099","phase":"PHASE4","title":"The Optimal Sequential Therapy After Long Term Denosumab Treatment","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-01-10","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT03292146","phase":"PHASE3","title":"Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-25","conditions":"Bone Density, Bone Loss, Anorexia Nervosa","enrollment":30},{"nctId":"NCT07216794","phase":"PHASE2","title":"Small Trial of Alendronate Impact on the Reservoir of HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-17","conditions":"HIV","enrollment":30},{"nctId":"NCT04708886","phase":"PHASE2","title":"Romosozumab in Women With Chronic SCI","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2021-03-01","conditions":"Osteoporosis, Bone Loss, Osteopenia, Osteoporosis","enrollment":12},{"nctId":"NCT01648686","phase":"NA","title":"Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-09-19","conditions":"Alveolar Bone Healing After Dental Extraction","enrollment":66},{"nctId":"NCT05493761","phase":"PHASE4","title":"Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-12-23","conditions":"Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal","enrollment":72},{"nctId":"NCT07028320","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-12-03","conditions":"Postmenopausal Women With Osteoporosis","enrollment":493},{"nctId":"NCT05575167","phase":"","title":"Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-28","conditions":"Osteoporosis, Postmenopausal","enrollment":125},{"nctId":"NCT05151484","phase":"PHASE4","title":"Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover","status":"RECRUITING","sponsor":"Madhumathi Rao","startDate":"2022-03-21","conditions":"Age-Related Osteoporosis","enrollment":60},{"nctId":"NCT06264609","phase":"PHASE4","title":"Precision Medicine Approach for Osteoporosis - Follow Up Study","status":"ENROLLING_BY_INVITATION","sponsor":"Paul F Netzel","startDate":"2024-02-01","conditions":"Osteoporosis","enrollment":40},{"nctId":"NCT06864130","phase":"PHASE4","title":"A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-02-21","conditions":"Osteoporosis in Post-menopausal Women","enrollment":1400},{"nctId":"NCT06856369","phase":"PHASE4","title":"Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bahria University","startDate":"2025-01-22","conditions":"Alveolar Bone Loss Associated Chronic Periodontitis","enrollment":120},{"nctId":"NCT01631214","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-04","conditions":"Postmenopausal Women With Osteoporosis","enrollment":4093},{"nctId":"NCT06772792","phase":"PHASE1","title":"A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-23","conditions":"Healthy","enrollment":36},{"nctId":"NCT04403698","phase":"PHASE2","title":"The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-11-13","conditions":"Erosive Osteoarthritis","enrollment":30},{"nctId":"NCT04177940","phase":"PHASE4","title":"Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-17","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT04338529","phase":"","title":"Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation","status":"COMPLETED","sponsor":"251 Hellenic Air Force & VA General Hospital","startDate":"2020-04-01","conditions":"Postmenopausal Osteoporosis","enrollment":92},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT06621069","phase":"","title":"The Effect of Long-term Use of Bisphosphonates on Femur Morphology","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-06-01","conditions":"Osteoporosis, Knee Osteoarthristis","enrollment":140},{"nctId":"NCT05602493","phase":"PHASE3","title":"A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xeolas Pharmaceuticals Limited","startDate":"2022-11-22","conditions":"Bone Loss, Alveolar","enrollment":60},{"nctId":"NCT00092040","phase":"PHASE3","title":"A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03-18","conditions":"Osteoporosis, Postmenopausal","enrollment":936},{"nctId":"NCT00480766","phase":"PHASE3","title":"A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07","conditions":"Osteoporosis","enrollment":173},{"nctId":"NCT00092066","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-24","conditions":"Osteoporosis, Vitamin D Deficiency","enrollment":717},{"nctId":"NCT00480662","phase":"PHASE3","title":"A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10","conditions":"Paget's Disease of Bone","enrollment":60},{"nctId":"NCT00092014","phase":"PHASE3","title":"A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09-01","conditions":"Postmenopausal Osteoporosis","enrollment":1053},{"nctId":"NCT00092027","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03-19","conditions":"Postmenopausal Osteoporosis","enrollment":454},{"nctId":"NCT00389740","phase":"PHASE3","title":"A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-04-02","conditions":"Osteoporosis, Postmenopausal","enrollment":400},{"nctId":"NCT06264401","phase":"NA","title":"Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-02-01","conditions":"Postmenopausal Osteoporosis","enrollment":60},{"nctId":"NCT03542695","phase":"EARLY_PHASE1","title":"64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2021-11-03","conditions":"Breast Carcinoma, Calcification","enrollment":1},{"nctId":"NCT01350934","phase":"PHASE4","title":"A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-19","conditions":"Osteoporosis, Postmenopausal","enrollment":219},{"nctId":"NCT00692913","phase":"PHASE3","title":"A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-06","conditions":"Osteoporosis","enrollment":515},{"nctId":"NCT03396315","phase":"PHASE2","title":"Bisphosphonates for Prevention of Post-Denosumab Bone Loss","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-01-29","conditions":"IOP, Osteoporosis","enrollment":24},{"nctId":"NCT00729651","phase":"PHASE4","title":"Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-03-20","conditions":"Osteoporosis Postmenopausal","enrollment":343},{"nctId":"NCT01437111","phase":"PHASE3","title":"Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-10-26","conditions":"Osteoporosis","enrollment":200},{"nctId":"NCT00019695","phase":"PHASE2","title":"Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-03","conditions":"Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate","enrollment":""},{"nctId":"NCT05527548","phase":"PHASE4","title":"A Single-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2022-12-22","conditions":"ACL Reconstruction","enrollment":64},{"nctId":"NCT02944799","phase":"PHASE2","title":"Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-12","conditions":"Rheumatoid Arthritis, Osteoporosis","enrollment":69},{"nctId":"NCT04555317","phase":"NA","title":"Bone Toxicity Following Pelvic Radiotherapy","status":"UNKNOWN","sponsor":"The Christie NHS Foundation Trust","startDate":"2021-05-17","conditions":"Gynecologic Cancer, Radiotherapy Side Effect, Fracture","enrollment":80},{"nctId":"NCT01460654","phase":"PHASE2","title":"Testosterone and Alendronate in Hypogonadal Men","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2011-10","conditions":"Hypogonadism, Osteopenia, Osteoporosis","enrollment":44},{"nctId":"NCT00580047","phase":"NA","title":"Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2003-12-01","conditions":"Renal Insufficiency","enrollment":59},{"nctId":"NCT03623633","phase":"PHASE4","title":"Comparative Antiresorptive Efficacy Discontinuation of Denosumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-11-30","conditions":"Osteoporosis, Postmenopausal, Osteoporosis","enrollment":51},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT02195895","phase":"PHASE2","title":"Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2014-04","conditions":"Spinal Cord Injury, Bone Loss, Osteoporosis","enrollment":17},{"nctId":"NCT05771038","phase":"EARLY_PHASE1","title":"Assessment of Bone Quality After Socket Preservation Using Sodium Alendronate Gel Compared to Sticky Bone","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-04","conditions":"Bone Quality Assessment, Preserved Sockets, Sodium Alendronate","enrollment":32},{"nctId":"NCT05662358","phase":"NA","title":"Denosumab vs Alendronate After Vertebroplasty","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2021-01-03","conditions":"Denosumab Allergy","enrollment":90},{"nctId":"NCT05325515","phase":"PHASE4","title":"The Effect of Effervescent Alendronate on Bone Turnover","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2021-10-01","conditions":"Osteopenia or Osteoporosis","enrollment":64},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT02440581","phase":"NA","title":"Renal Osteodystrophy: An Individual Management Approach","status":"COMPLETED","sponsor":"Hartmut Malluche, MD","startDate":"2015-07-01","conditions":"Kidney Failure, Chronic","enrollment":141},{"nctId":"NCT05645289","phase":"PHASE4","title":"Efficacy and Safety of Minodronate in Patients With Low Back Pain","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-01-01","conditions":"Postmenopausal Osteoporosis","enrollment":72},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":"Low Bone Mineral Density, Postmenopausal Osteoporosis","enrollment":419},{"nctId":"NCT05397938","phase":"PHASE2","title":"Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-06-15","conditions":"Glucocorticoid Induced Osteoporosis","enrollment":231},{"nctId":"NCT05387200","phase":"PHASE4","title":"Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-07-02","conditions":"Osteoporosis","enrollment":170},{"nctId":"NCT02322099","phase":"PHASE4","title":"Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-05","conditions":"Bone Demineralization","enrollment":53},{"nctId":"NCT04739592","phase":"PHASE4","title":"A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-07","conditions":"Knee Osteoarthritis","enrollment":60},{"nctId":"NCT05305183","phase":"PHASE3","title":"A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-05-31","conditions":"Osteoporosis","enrollment":330},{"nctId":"NCT00806416","phase":"PHASE1","title":"A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Osteoporosis","enrollment":244},{"nctId":"NCT01065779","phase":"","title":"FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Osteoporosis","enrollment":880},{"nctId":"NCT00803790","phase":"PHASE1","title":"A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05","conditions":"Osteoporosis","enrollment":318},{"nctId":"NCT00398931","phase":"PHASE3","title":"FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1998-02","conditions":"Osteoporosis, Postmenopausal","enrollment":1099},{"nctId":"NCT00398606","phase":"PHASE3","title":"A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-04","conditions":"Osteoporosis, Postmenopausal","enrollment":650},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":"Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma","enrollment":684815},{"nctId":"NCT00641771","phase":"PHASE1","title":"4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-05","conditions":"Osteoporosis","enrollment":56},{"nctId":"NCT05162885","phase":"EARLY_PHASE1","title":"Effect of Sodium Alendronate on the Final Implant Stability.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-05-01","conditions":"Anterior Labial Wall Defect","enrollment":24},{"nctId":"NCT02304757","phase":"NA","title":"99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":"Differentiated Thyroid Cancer, Osteoporosis","enrollment":142},{"nctId":"NCT04169698","phase":"PHASE2, PHASE3","title":"Alendronate Versus Denosumab in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-10-17","conditions":"Osteoporosis, Osteopenia, Renal Transplant Recipient","enrollment":90},{"nctId":"NCT00921557","phase":"PHASE2","title":"Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":"HIV Infection","enrollment":52},{"nctId":"NCT02132026","phase":"PHASE2","title":"Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-11-12","conditions":"Calcific Aortic Stenosis","enrollment":152},{"nctId":"NCT02371252","phase":"PHASE4","title":"Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2014-04","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT03197623","phase":"PHASE1","title":"Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids","status":"COMPLETED","sponsor":"Nancy E. Lane, MD","startDate":"2016-10-14","conditions":"Osteopenia, Osteoporosis, Osteonecrosis","enrollment":58},{"nctId":"NCT04861142","phase":"","title":"Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy","status":"UNKNOWN","sponsor":"University General Hospital of Heraklion","startDate":"2021-04-23","conditions":"Osteoporosis","enrollment":350},{"nctId":"NCT03051620","phase":"","title":"Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2017-02-01","conditions":"Osteoporosis","enrollment":142},{"nctId":"NCT04719572","phase":"NA","title":"Intervention Study of Drugs in Patients Osteopenia and Osteoporosis","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03","conditions":"Osteoporosis, Osteopenia, Osteoporosis","enrollment":180},{"nctId":"NCT04704947","phase":"PHASE3","title":"Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2017-10-01","conditions":"Beta Blocker Toxicity","enrollment":50},{"nctId":"NCT01657162","phase":"PHASE3","title":"Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis","status":"COMPLETED","sponsor":"Radius Health, Inc.","startDate":"2012-11-20","conditions":"Postmenopausal Osteoporosis","enrollment":1139},{"nctId":"NCT03435094","phase":"","title":"Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes","status":"UNKNOWN","sponsor":"Labatec Pharma SA","startDate":"2018-02-25","conditions":"Osteoporosis, Postmenopausal","enrollment":80},{"nctId":"NCT02781805","phase":"PHASE1","title":"Pilot Study of Bisphosphonates for Breast Cancer","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2016-08-05","conditions":"Breast Neoplasms","enrollment":6},{"nctId":"NCT01656629","phase":"NA","title":"Stem Cell Recruitment in Osteoporosis Therapy","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Low Bone Density","enrollment":55},{"nctId":"NCT00919711","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-09-01","conditions":"Osteoporosis","enrollment":870},{"nctId":"NCT00354302","phase":"PHASE3","title":"Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-04-24","conditions":"Breast Cancer, Osteoporosis","enrollment":497},{"nctId":"NCT03005678","phase":"PHASE4","title":"Denosumab Versus Bisphosphonates (Alendronate) in GIOP","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2017-04-01","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT00421343","phase":"PHASE3","title":"Secondary Prevention of Osteoporosis","status":"COMPLETED","sponsor":"Hebrew SeniorLife","startDate":"2007-02","conditions":"Osteoporosis","enrollment":29},{"nctId":"NCT00518531","phase":"PHASE3","title":"Denosumab Adherence Preference Satisfaction Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-09-01","conditions":"Osteoporosis","enrollment":250},{"nctId":"NCT04140006","phase":"PHASE1, PHASE2","title":"Efficacy of Antiresorptive and Bone Forming Material on Dental Implants","status":"UNKNOWN","sponsor":"University of Baghdad","startDate":"2019-07-01","conditions":"Partial Edentulism","enrollment":20},{"nctId":"NCT03980847","phase":"PHASE2","title":"Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Alendronate in the Preservation of the Tooth Socket","status":"COMPLETED","sponsor":"Islamic Azad University, Sanandaj","startDate":"2018-02-23","conditions":"Bone Resorption","enrollment":20},{"nctId":"NCT01588509","phase":"PHASE1","title":"Transition From Alendronate to Romosozumab (AMG 785)","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-30","conditions":"Osteoporosis","enrollment":60},{"nctId":"NCT01526278","phase":"PHASE1","title":"Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Yuyu Pharma, Inc.","startDate":"2011-10","conditions":"Osteoporosis","enrollment":18},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":"Postmenopausal Osteoporosis","enrollment":86},{"nctId":"NCT01512446","phase":"PHASE3","title":"Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy","status":"TERMINATED","sponsor":"Evangelisches Krankenhaus Lutherhaus gGmbH","startDate":"2012-02","conditions":"Osteoporosis","enrollment":436},{"nctId":"NCT03006003","phase":"PHASE4","title":"Osteoporosis Treatment in Post-menopausal Women","status":"UNKNOWN","sponsor":"Taichung Veterans General Hospital","startDate":"2017-01-01","conditions":"Depressive Syndrome","enrollment":500},{"nctId":"NCT02731040","phase":"","title":"Exome Sequencing for Atypical Femoral Fractures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":"Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy","enrollment":38},{"nctId":"NCT03692143","phase":"","title":"Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-01-01","conditions":"Osteoporosis, Postmenopausal, Vertebral Fracture, Quality of Life","enrollment":90},{"nctId":"NCT00145977","phase":"NA","title":"Texture Analysis for Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-07","conditions":"Osteoporosis, Osteopenia","enrollment":36},{"nctId":"NCT01101048","phase":"PHASE1","title":"An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06","conditions":"Osteopenia","enrollment":74}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"SEPSIS"},{"count":1,"reaction":"ACUTE MYOCARDIAL INFARCTION"},{"count":1,"reaction":"BAND NEUTROPHIL COUNT INCREASED"},{"count":1,"reaction":"BONE DISORDER"},{"count":1,"reaction":"BRAIN NATRIURETIC PEPTIDE INCREASED"},{"count":1,"reaction":"BRONCHIECTASIS"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":1,"reaction":"CONFUSIONAL STATE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fosamax"],"phase":"marketed","status":"active","brandName":"Alendronate (Fosamax)","genericName":"Alendronate (Fosamax)","companyName":"Medical University of South Carolina","companyId":"medical-university-of-south-carolina","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alendronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and blocking the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Osteoporosis in postmenopausal women, Osteoporosis in men, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}